1961
DOI: 10.1210/jcem-21-2-201
|View full text |Cite
|
Sign up to set email alerts
|

EFFECT OF o,p′DDD IN A PATIENT WITH CUSHING'S SYNDROME*

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
3
0

Year Published

1963
1963
2015
2015

Publication Types

Select...
5
3

Relationship

1
7

Authors

Journals

citations
Cited by 34 publications
(3 citation statements)
references
References 0 publications
0
3
0
Order By: Relevance
“…The efficacy of mitotane has been reported in several studies (298,572,(574)(575)(576)(577)(578)(579)(580)(581)(582),including,beyondcasereports,fourmain studies (298,577,578,582). These main studies included 173 patients with CD; the drug dose ranged from 0.9 to 12 g, with follow-up ranging from 0.3 to 114.9 months (mean, 15.1 mo) doi: 10.1210/er.2013-1048 press.endocrine.org/journal/edrv 437 (298,577,578,582).…”
Section: Mitotanementioning
confidence: 99%
“…The efficacy of mitotane has been reported in several studies (298,572,(574)(575)(576)(577)(578)(579)(580)(581)(582),including,beyondcasereports,fourmain studies (298,577,578,582). These main studies included 173 patients with CD; the drug dose ranged from 0.9 to 12 g, with follow-up ranging from 0.3 to 114.9 months (mean, 15.1 mo) doi: 10.1210/er.2013-1048 press.endocrine.org/journal/edrv 437 (298,577,578,582).…”
Section: Mitotanementioning
confidence: 99%
“…This observation led to the development of the use of o,p 0 -DDD or mitotane, initially for adrenal cancer and CS (Cueto & Brown 1958, Southren et al 1961. Subsequently, amphonenone B , Thorn et al 1956), aminoglutethimide (Camacho et al 1967), metyrapone (Gower 1974), trilostane (Potts et al 1978), and ketoconazole (Pont et al 1982) were identified as steroidogenic inhibitors ( Fig.…”
Section: Adrenal Steroidogenesis Blockersmentioning
confidence: 99%
“…Mitotane was introduced as a treatment for adrenal carcinoma in 1960,41 and appears to cause tumor regression and improved survival in some patients, and has a beneficial effect on endocrine hypersecretion in approximately 75% of patients 42. It was subsequently reported as a treatment for hypercortisolemia in Cushing's syndrome a year later 43. In a large study of the effects of mitotane in 62 patients with Cushing's disease, of 46 patients who received mitotane alone, 38 showed remission on the basis of urinary 17‐hydroxycorticosteroids at a mean of 8 months on treatment 44.…”
Section: Adrenolytic Therapymentioning
confidence: 99%